Cambium Bio Ltd

AU:CMB Australia Biotechnology
Market Cap
$6.83 Million
AU$11.02 Million AUD
Market Cap Rank
#29456 Global
#810 in Australia
Share Price
AU$0.48
Change (1 day)
+0.00%
52-Week Range
AU$0.19 - AU$0.60
All Time High
AU$22.97
Categories
Companies in Australia Biotechnology
About

Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. The company provides lead product candidate is Elate Ocular for the treatment of dry eye disease. The company also develops Progenza, a stem cell platform for knee osteoarthritis and other tissue repair indications; and Sygenus, for wound healing i… Read more

Cambium Bio Ltd (CMB) - Net Assets

Latest net assets as of June 2025: AU$1.84 Million AUD

Based on the latest financial reports, Cambium Bio Ltd (CMB) has net assets worth AU$1.84 Million AUD as of June 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$3.30 Million) and total liabilities (AU$1.46 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets AU$1.84 Million
% of Total Assets 55.71%
Annual Growth Rate -15.13%
5-Year Change -55.72%
10-Year Change -61.63%
Growth Volatility 145.79

Cambium Bio Ltd - Net Assets Trend (1999–2025)

This chart illustrates how Cambium Bio Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Cambium Bio Ltd (1999–2025)

The table below shows the annual net assets of Cambium Bio Ltd from 1999 to 2025.

Year Net Assets Change
2025-06-30 AU$1.84 Million -33.88%
2024-06-30 AU$2.78 Million +242.33%
2023-06-30 AU$-1.95 Million -281.49%
2022-06-30 AU$1.07 Million -74.07%
2021-06-30 AU$4.15 Million +278.91%
2020-06-30 AU$1.09 Million +117.13%
2019-06-30 AU$-6.39 Million -318.58%
2018-06-30 AU$2.92 Million -63.93%
2017-06-30 AU$8.10 Million +69.29%
2016-06-30 AU$4.78 Million -42.16%
2015-06-30 AU$8.27 Million -0.43%
2014-06-30 AU$8.31 Million +389.60%
2013-06-30 AU$-2.87 Million -247.22%
2012-06-30 AU$1.95 Million -40.72%
2011-06-30 AU$3.29 Million +139.78%
2010-06-30 AU$1.37 Million -96.62%
2002-06-30 AU$40.54 Million -79.34%
2001-06-30 AU$196.21 Million +21.80%
2000-06-30 AU$161.09 Million +23.39%
1999-06-30 AU$130.56 Million --

Equity Component Analysis

This analysis shows how different components contribute to Cambium Bio Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 215.5% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (June 2025)

Component Amount Percentage
Common Stock AU$46.54 Million 2535.25%
Other Comprehensive Income AU$1.89 Million 102.74%
Total Equity AU$1.84 Million 100.00%

Cambium Bio Ltd Competitors by Market Cap

The table below lists competitors of Cambium Bio Ltd ranked by their market capitalization.

Company Market Cap
Heart Test Laboratories Inc. Common Stock
NASDAQ:HSCS
 		$8.11 Million
Jufan Industrial Co., Ltd.
TWO:4584
 		$8.11 Million
Wijaya Karya Bangunan Gedung Tbk PT
JK:WEGE
 		$8.11 Million
Cara Therapeutic
NASDAQ:CARA
 		$8.11 Million
TEKMAR GROUP PLC LS-01
F:6UA
 		$8.10 Million
Gihon Telekomunikasi Indonesia Tbk PT
JK:GHON
 		$8.10 Million
Komputronik S.A.
WAR:KOM
 		$8.09 Million
Elah Holdings Inc
PINK:ELLH
 		$8.09 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Cambium Bio Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 2,776,331 to 1,835,748, a change of -940,583 (-33.9%).
  • Net loss of 3,844,251 reduced equity.
  • New share issuances of 2,880,707 increased equity.
  • Other comprehensive income decreased equity by 4,961.
  • Other factors increased equity by 27,922.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income AU$-3.84 Million -209.41%
Share Issuances AU$2.88 Million +156.92%
Other Comprehensive Income AU$-4.96K -0.27%
Other Changes AU$27.92K +1.52%
Total Change AU$- -33.88%

Book Value vs Market Value Analysis

This analysis compares Cambium Bio Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 4.78x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has increased from 0.71x to 4.78x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1999-06-30 AU$0.67 AU$0.48 x
2000-06-30 AU$0.82 AU$0.48 x
2001-06-30 AU$0.96 AU$0.48 x
2002-06-30 AU$0.21 AU$0.48 x
2010-06-30 AU$0.01 AU$0.48 x
2011-06-30 AU$1.69 AU$0.48 x
2012-06-30 AU$1.00 AU$0.48 x
2013-06-30 AU$-1.48 AU$0.48 x
2014-06-30 AU$4.88 AU$0.48 x
2015-06-30 AU$3.95 AU$0.48 x
2016-06-30 AU$2.24 AU$0.48 x
2017-06-30 AU$3.79 AU$0.48 x
2018-06-30 AU$1.37 AU$0.48 x
2019-06-30 AU$-2.99 AU$0.48 x
2020-06-30 AU$0.41 AU$0.48 x
2021-06-30 AU$0.01 AU$0.48 x
2022-06-30 AU$0.35 AU$0.48 x
2023-06-30 AU$-0.59 AU$0.48 x
2024-06-30 AU$0.67 AU$0.48 x
2025-06-30 AU$0.10 AU$0.48 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Cambium Bio Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -209.41%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -573.72%
  • • Asset Turnover: 0.20x
  • • Equity Multiplier: 1.79x
  • Recent ROE (-209.41%) is below the historical average (-77.79%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1999 11.78% 9.49% 0.56x 2.21x AU$2.28 Million
2000 17.64% 14.05% 0.67x 1.86x AU$11.87 Million
2001 11.14% 9.86% 0.63x 1.78x AU$2.09 Million
2002 -209.91% -41.24% 4.02x 1.27x AU$-87.16 Million
2011 -52.40% -219.21% 0.19x 1.28x AU$-2.05 Million
2012 -167.34% -274.90% 0.36x 1.69x AU$-3.46 Million
2013 0.00% -302.22% 0.43x 0.00x AU$-4.91 Million
2014 -90.55% -395.53% 0.19x 1.23x AU$-8.35 Million
2015 -79.86% -362.93% 0.19x 1.16x AU$-7.43 Million
2016 -74.69% -205.93% 0.29x 1.24x AU$-4.05 Million
2017 40.38% 32.73% 1.09x 1.13x AU$2.46 Million
2018 -177.45% -901.03% 0.12x 1.71x AU$-5.48 Million
2019 0.00% -24024.40% 0.01x 0.00x AU$-5.39 Million
2020 -81.72% -53.75% 0.35x 4.38x AU$-1.00 Million
2021 66.56% 39.04% 0.83x 2.05x AU$2.34 Million
2022 -400.98% 0.00% 0.00x 2.38x AU$-4.42 Million
2023 0.00% 0.00% 0.00x 0.00x AU$-3.20 Million
2024 -81.25% -313736.44% 0.00x 2.03x AU$-2.53 Million
2025 -209.41% -573.72% 0.20x 1.79x AU$-4.03 Million

Industry Comparison

This section compares Cambium Bio Ltd's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $34,431,628
  • Average return on equity (ROE) among peers: -58.73%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Cambium Bio Ltd (CMB) AU$1.84 Million 11.78% 0.79x $8.11 Million
Adalta Ltd (1AD) $2.03 Million -265.03% 1.74x $171.91K
Algorae Pharmaceuticals Ltd (1AI) $2.88 Million -33.65% 0.18x $9.99 Million
ACRUX Ltd (ACR) $17.49 Million -17.99% 0.05x $2.16 Million
Argenica Therapeutics Ltd (AGN) $13.95 Million -39.28% 0.17x $11.42 Million
Arovella Therapeutics Ltd (ALA) $11.23 Million -77.89% 0.18x $39.76 Million
Anatara Lifesciences Ltd (ANR) $5.92 Million -48.49% 0.08x $718.75K
Bio-Gene Technology Ltd (BGT) $4.25 Million -56.43% 0.18x $2.33 Million
BTC Health Ltd (BTC) $11.34 Million -4.81% 0.03x $364.22
Clinuvel Pharmaceuticals Ltd (CUV) $240.81 Million 15.02% 0.13x $251.65 Million